Analytical Data
-
Gene name
PCDH10
-
简介
The PCDH10 protein is a putative calcium-dependent cell adhesion protein implicated in mediating cell-cell interactions. Its response to intracellular calcium levels is characteristic of cell adhesion molecules, suggesting a role in cell recognition, adhesion and signaling. PCDH10 Protein, Human (L405P, HEK293, His) is the recombinant human-derived PCDH10 protein, expressed by HEK293 , with C-6*His labeled tag and L405P mutation.
- Application
-
Alternative Names
Protocadherin-10; PCDH10; KIAA1400
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9P2E7-1
-
Expression Region
Q19-T715, L405P
-
AA Sequence
QLHYTVQEEQEHGTFVGNIAEDLGLDITKLSARGFQTVPNSRTPYLDLNLETGVLYVNEKIDREQICKQSPSCVLHLEVFLENPLELFQVEIEVLDINDNPPSFPEPDLTVEISESATPGTRFPLESAFDPDVGTNSLRDYEITPNSYFSLDVQTQGDGNRFAELVLEKPLDREQQAVHRYVLTAVDGGGGGGVGEGGGGGGGAGLPPQQQRTGTALLTIRVLDSNDNVPAFDQPVYTVSLPENSPPGTLVIQLNATDPDEGQNGEVVYSFSSHISPRARELFGLSPRTGRLEVSGELDYEESPVYQVYVQAKDLGPNAVPAHCKVLVRVLDANDNAPEISFSTVKEAVSEGAAPGTVVALFSVTDRDSEENGQVQCELLGDVPFRPKSSFKNYYTIVTEAPLDREAGDSYTLTVVARDRGEPALSTSKSIQVQVSDVNDNAPRFSQPVYDVYVTENNVPGAYIYAVSATDRDEGANAQLAYSILECQIQGMSVFTYVSINSENGYLYALRSFDYEQLKDFSFQVEARDAGSPQALAGNATVNILIVDQNDNAPAIVAPLPGRNGTPAREVLPRSAEPGYLLTRVAAVDADDGENARLTYSIVRGNEMNLFRMDWRTGELRTARRVPAKRDPQRPYELVIEVRDHGQPPLSSTATLVVQLVDGAVEPQGGGGSGGGGSGEHQRPSRSGGGETSLDLT
-
Protein Length
Extracellular Domain
-
Molecular Weight
93.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPNMB, also known as Osteoactivin, is a glycoprotein that plays a significant role in various biological processes, including bone remodeling, inflammation, and cancer progression. Initially identified for its involvement in osteoblast differentiation and function, GPNMB has gained attention for its diverse functions in different tissues, suggesting its potential as a therapeutic target. Research indicates that GPNMB is overexpressed in several malignancies, including melanoma and breast cancer, where it correlates with poor prognosis and metastasis. This has prompted investigations into the molecular mechanisms underlying GPNMB's role in tumor biology, revealing its involvement in promoting cell survival, migration, and immune evasion. Furthermore, studies have demonstrated that GPNMB exerts regulatory effects on the immune system, contributing to the outcomes of autoimmune diseases and chronic inflammation. The recombinant production of GPNMB offers an opportunity to investigate its bioactivity more thoroughly and to explore its therapeutic potential. By generating and characterizing recombinant GPNMB, researchers aim to elucidate its role in pathological conditions and evaluate its utility as a biomarker or a target for novel therapeutic strategies. Understanding the structure-function relationship of GPNMB/Osteoactivin through recombinant protein studies can provide insights into its mechanisms of action and pave the way for interventions that modulate its effects in diseases. Overall, the ongoing research on recombinant GPNMB/Osteoactivin is essential for developing targeted therapies and improving patient outcomes in conditions associated with altered GPNMB expression.
